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Female endocrinology – 
What is it about?
Endocrinologia feminina – Do que se trata?
Dolores Pardini1, Ruth Clapauch2
T his edition of the Brazilian Archives of Endocrinology and Metabolism is dedi-cated to Female Endocrinology, a branch of Endocrinology committed to the 
study of hormonal regulation of the female reproductive system and its disturbances, 
from birth to old age. As women represent half of the world population, it is not 
surprising that Female Endocrinology is so popular among health professionals and 
women themselves. 
Female Endocrinology is a scientific department of the Brazilian Society of En-
docrinology (SBEM), together with Andrology (DEFA). The editors of the present 
issue are all past or current DEFA presidents: RC (2001-2002 and 2003-2004); PMS 
(2009-2010), and DPP is the present president (2013-2014). 
In this edition, an article on how endocrine disruptors may affect female genital 
tract development (1) opens the discussion on environmental influences on our bod-
ies. Rachel Carlson, who observed reproductive impairment and thus death of birds 
exposed to pesticides, first described endocrine disruptors in the late 1950s. Nowa-
days, we know that many of these compounds are persistent and interfere with the en-
docrine system (2), with estrogen receptor agonism as their first and most commonly 
described action. Bisphenol A (BPA) is a high production volume monomer used in 
the manufacture of a wide variety of polycarbonate plastics and resins used as dental 
sealants and as food packaging liners, all of which are formed from polymerization 
of BPA. The BPA molecule has structural features that are similar to 17β-estradiol 
and other natural estrogenic compounds found in foods (e.g. daidzein in soy prod-
ucts), which give them the ability to bind to estrogen receptors, when present in high 
enough concentrations.
Estrogen-like influences and weight gain may, in part, explain why the age of pu-
berty is decreasing to less than 10 years old. In this issue, central precocious puberty is 
addressed (3) in relation to its etiology, diagnosis, and treatment. Precocious puberty 
may also be a sign of polycystic ovary syndrome (PCOS). 
PCOS is a very important chapter of female endocrinology, a disorder of meta-
bolic, as well as reproductive function; common (although not universal) co-morbid-
ities include insulin resistance, hyperinsulinemia, dyslipidemia, hepatic steatosis, and a 
predisposition to type 2 diabetes and cardiovascular disease. Sixty percent of patients 
with PCOS are overweight or obese, and even “normal-weight” subjects have relative 
visceral adiposity and heightened production of inflammatory adipocytokines (4,5).
Hirsutism is another feature of PCOS that represents major discomfort among 
adolescent and young adults. A brief review on hirsutism diagnosis and treatment is 
also part of this issue. 
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Prolactin disorders may represent a problem in this 
context, and they are fully addressed in this issue as 
well. 
Moving into the reproductive years, an up-to-date 
approach on how to assess ovulation in fertility-seeking 
women and how to discover if an endocrine disorder 
is affecting fertility is shown in this issue. This is ba-
sic knowledge for the endocrinologist who whishes 
to follow his patients up, and assist them in their re-
productive needs. Traditionally, reduced fertility and 
pregnancy rates have been reported in women with 
classic CAH. Fertility rates of 60-80% and 7-60% have 
been reported in women with classic SV and classic SW 
CAH, respectively. In contrast to reduced fertility in 
classic CAH, pregnancies are commonly normal and 
uneventful. Thus, fertility, rather than pregnancy rates, 
seems to be reduced compared with the general popu-
lation. Subfertility in females with classic CAH is due to 
several contributing factors, including androgen excess, 
adrenal progesterone hypersecretion, consequences 
of genital reconstructive surgery, secondary polycystic 
ovaries syndrome, ovarian adrenal rest tumors, and psy-
chosexual factors (6).
In this edition, we also approach hormonal therapy 
in transsexual people in this issue. The rationale for 
medical assessment of transsexual patient lies in the 
fact that this population is at high risk of suicide, self-
mutilation, and depression due to lack of healthcare 
support. Moreover, the real positive effect of hormone 
therapy on transsexuals quality of life has been demon-
strated (7).
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